Nava Bharat Ventures Limited (NBV) operates in the business verticals of power generation, mining, ferro alloys and agri-business with operations spread over India and Africa. The Company’s shares are listed on
under the scrip IDs : NBVENTURES & NBVENTURE respectively.
The Company’s major business segment is power generation. It produces thermal power using coal and bio-mass in India. The company has established and commissioned, through its subsidiary Maamba Collieries Limited in Zambia, a 300MW mine-mouth, thermal power plant at Maamba in Southern Africa.
The coal mining activity is carried out by Maamba Collieries Limited, a step-down subsidiary of NBV. This is the largest coal mining concession in Zambia. The high grade coal produced is supplied to various process industries while the thermal grade coal will meet the fuel requirement of the 300MW power plant (Phase-I) commissioned at the mine.
NBV is a leading manufacturer exporter of manganese and chromium ferro alloys from India. These alloys are key inputs for manufacture steel of various specifications including stainless steels. The company supplies its products to steel manufacturers in India and various other countries. The major export markets are the US, the European countries, Middle East and Japan.
NBV operates an integrated sugar complex with high energy efficiency, producing sugar, rectified spirit and ethanol , aside from co-generation of power at Samalkot, Andhra Pradesh, India. The Company proposes to geographically diversify its agri-business by establishing an integrated sugar complex in Zambia. The Zambian subsidiary is engaged in preliminary development works on the 10,000 ha of land, allocated by the Government for this purpose. This project would enable the NBV group to leverage its rich experience in agri-related businesses, in Africa, starting with the proposed sugar complex in Zambia.
The Group has identified Health care enabled service in addressing Iron Deficiency as an emerging opportunity in Asia Pacific region covering Singapore and Malaysia. It has taken a majority investment position in a cluster of companies, engaged in distribution to administration of the prescribed formulations. Though the size of investment is low at a maximum US$ 11 Million over a four year period, the Group considers it to provide the necessary footprint to access other related businesses in due course and therefore deems this investment as a strategic diversification into B2C segment.